Pharmaceutical manufacturing to reach US$673.6bn by 2027
Based on comprehensive research of the global pharmaceutical manufacturing industry, the report findings are said to be driven by five key areas:
- Increased drug approval
- Increasing chronic ailments
- A growing geriatric population
- High research and development investments,
- Increasing healthcare expenditure as a result of COVID-19
ResearchAndMarkets.com outlook for the global industry is forecasted with optimistic, balanced and conservative views, taking into account the impact of COVID-19.
In the report, ResearchAndMarkets.com covers competitive scenarios and predicted trends, as well as the profiles of key vendors, leaders and emerging players in the markets, and the potential risks associated with investing in the global pharmaceutical manufacturing industry.
ResearchAndMarkets.com has also generated Critical Success Factors (CSFs) to provide investors & stockholders with guidance when it comes to identifying emerging opportunities, managing and minimising the risks, developing appropriate business models, and making wise strategies and decisions.
Key players in the industry include: Abbott Laboratories, Aenova Group, Amgen, AstraZeneca, Catalent Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, GlaxoSmithKline plc, Johnson & Johnson, Lonza Group, Lupin, Merck & Co. Inc., Novartis AG, Novo Nordisk, Pfizer, Inc., Roche, Sanofi SA, and Takeda.